Comparative Pharmacology
Head-to-head clinical analysis: PHENYTEX versus ZONEGRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYTEX versus ZONEGRAN.
PHENYTEX vs ZONEGRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by promoting sodium efflux and inhibiting calcium influx, thereby reducing repetitive firing of action potentials. Also enhances GABA-mediated inhibition.
Anticonvulsant; blocks voltage-gated sodium and calcium channels, enhances GABA-mediated inhibition, and inhibits glutamate release.
300-400 mg/day orally in divided doses, typically 100 mg three times daily or 200 mg twice daily; loading dose 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) at 2-hour intervals, or 10-15 mg/kg IV at a rate not exceeding 50 mg/min.
Initial: 100 mg orally once daily for 2 weeks, then may increase by 100 mg/day at 2-week intervals; usual maintenance: 200-400 mg/day divided once or twice daily; maximum: 600 mg/day.
None Documented
None Documented
22 hours (range 7-42 hours; prolonged in hepatic impairment; clinical context: steady-state achieved in 5-7 days)
Terminal elimination half-life is approximately 63 hours (range 50-70 hours) in adults. The long half-life allows for once- or twice-daily dosing. Steady state is reached after about 2 weeks of repeated dosing.
Renal (hepatic metabolism to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal excretion minimal)
Renal: approximately 62% of the dose as unchanged drug and metabolites (primarily glucuronide conjugates and N-acetylzonisamide). Fecal: approximately 16% (including metabolites). Biliary excretion is minimal. Total recovery in urine and feces accounts for ~80% of the dose.
Category C
Category C
Anticonvulsant
Anticonvulsant